Biofrontera stock analysis
Biofrontera (0DOL) Share Price & Analysis
0DOL Stock Chart & Stats
- Day’s Range
- EUR 2.88 - EUR 2.88
- 52-Week Range
- EUR 2.24 - EUR 14.30
- Previous Close
- EUR 3.11
- Volume
- N/A
- Average Volume (3M)
- 16
- Market Cap
- EUR 18.23M
- Enterprise Value
- EUR 11.99M
- Total Cash (Recent Filing)
- EUR 3.08M
- Total Debt (Recent Filing)
- EUR 1.15M
- Price to Earnings (P/E)
- ―
- Beta
- -0.50
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin
The approximately 83% gross margin indicates that Biofrontera’s products retain substantial value after direct production costs. If revenue stabilizes, this cost structure could support operating leverage, allowing incremental product sales to contribute more meaningfully toward covering commercial, research, and administrative expenses.
Conservative Leverage
Very low debt reduces interest burden and limits balance-sheet exposure to refinancing or creditor pressure. This gives Biofrontera greater flexibility to manage through weak profitability, preserve resources for dermatology products, and pursue recovery without the constraints associated with heavily leveraged financing.
Recurring PDT Product Model
The combination of PDT lamps and recurring topical gel consumption creates a business model with both equipment placement and treatment-linked product demand. A larger installed base and sustained clinician use could support repeat sales, making growth potentially more durable than a one-time product transaction.
Bears Say
Revenue Volatility
The sharp post-2023 revenue decline and only modest 2025 recovery show that Biofrontera has not yet established consistent commercial momentum. Continued volatility makes capacity planning and expense absorption more difficult, while limiting confidence that the current portfolio can reliably support sustainable growth.
Persistent Net Losses
Ongoing operating and net losses indicate that the company’s gross profit is not yet sufficient to fund its broader cost base. Even with some year-over-year improvement, persistent losses weaken internal funding capacity and leave profitability dependent on materially stronger revenue or further cost reductions.
Negative Cash Generation
Multi-year negative operating and free cash flow shows that the core business continues to consume cash rather than fund itself. This raises ongoing funding risk and can constrain investment in commercialization or development unless product sales scale, margins improve further, or operating costs are materially reduced.
Biofrontera News
0DOL FAQ
What was Biofrontera’s price range in the past 12 months?
What is Biofrontera’s market cap?
When is Biofrontera’s upcoming earnings report date?
How were Biofrontera’s earnings last quarter?
Is Biofrontera overvalued?
Does Biofrontera pay dividends?
What is Biofrontera’s EPS estimate?
How many shares outstanding does Biofrontera have?
What happened to Biofrontera’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Biofrontera?
What is the TipRanks Smart Score and how is it calculated?
Biofrontera Stock Smart Score
Company Description
Biofrontera
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Hermann Lübbert
- Employees
- 62
- Website
- www.biofrontera-us.com
- Address
- Hemmelrather Weg 201, Leverkusen, NW, 51377, DE
Biofrontera (0DOL) Earnings & Revenues
0DOL Earnings Call
Earnings Call SentimentPositive
The call presented meaningful operational and clinical progress: double-digit revenue growth (17% YoY), a substantial gross margin expansion to ~80% following the strategic transaction, near-breakeven operating cash usage ($70k), strong clinical/regulatory milestones (sNDA accepted with PDUFA date, positive Phase III AK data, encouraging acne Phase II), and regained NASDAQ compliance. Offsetting these positives are persistent GAAP losses (net loss $4.8M), higher SG&A (up ~27%), patent/legal and manufacturing transition costs, modest cash reserves ($6.3M) with a going concern qualification, and exposure to tariff/supply risks. Overall, the highlights—particularly the margin improvement, cash-flow progress, and clinical/regulatory advances—meaningfully outweigh the lowlights, though execution and financing risks remain.
View all GB:0DOL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 6 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 9 | 0 | 3 |
